<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769522</url>
  </required_header>
  <id_info>
    <org_study_id>CLL10</org_study_id>
    <secondary_id>CDR0000616169</secondary_id>
    <secondary_id>2007-007587-21</secondary_id>
    <nct_id>NCT00769522</nct_id>
  </id_info>
  <brief_title>FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>German CLL Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and
      bendamustine, work in different ways to stop the growth of cancer cells, either by killing
      the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can
      block cancer growth in different ways. Some block the ability of cancer cells to grow and
      spread. Others find cancer cells and help kill them or carry cancer-killing substances to
      them. It is not yet known whether giving fludarabine and cyclophosphamide together with
      rituximab is more effective than giving bendamustine together with rituximab in treating
      chronic lymphocytic leukemia.

      PURPOSE: This randomized phase III trial is studying fludarabine, cyclophosphamide, and
      rituximab to see how well they work compared with bendamustine and rituximab in treating
      patients with previously untreated B-cell chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To compare the therapeutic efficacy of fludarabine phosphate, cyclophosphamide, and
           rituximab vs bendamustine hydrochloride and rituximab in patients with previously
           untreated B-cell chronic lymphocytic leukemia.

        -  To compare the incidence of major side effects (e.g., myelosuppression) associated with
           these regimens in these patients.

        -  To compare the rate of infections and secondary neoplasias in patients treated with
           these regimens.

      OUTLINE: This is a multicenter study. Patients are stratified according to country and
      disease stage. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive fludarabine phosphate IV and cyclophosphamide IV on days 1-3.
           Patients also receive rituximab IV on day 0 of course 1 and on day 1 of courses 2-6.
           Treatment repeats every 28 days for 6 courses in the absence of disease progression or
           unacceptable toxicity.

        -  Arm II: Patients receive bendamustine hydrochloride IV on days 1 and 2. Patients also
           receive rituximab as in arm I. Treatment repeats every 28 days for 6 courses in the
           absence of disease progression or unacceptable toxicity.

      Patients complete quality of life questionnaires (EORTC-C30 and EURO-QOL) at baseline and
      then at 12, 24, 36, 48, and 60 months.

      After completion of study therapy, patients are followed every 3 months for 2 years, every 6
      months for 3 years, and then once a year thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2008</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate after 24 months</measure>
    <time_frame>2008-2015</time_frame>
    <description>estimated time point when 198 needed events for the final analysis(PD or deaths) have occured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease, complete response rates, and partial response rates</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates in and survival times in biological subgroups</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity rates</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard safety analysis</measure>
    <time_frame>2008-2015</time_frame>
    <description>done within the final analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">564</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>FCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>cycle 1: 375 mg/m² i.v., day 0, q28d
cycle 2-6: 500 mg/m² i.v., day 1, q28d</description>
    <arm_group_label>FCR</arm_group_label>
    <arm_group_label>BR</arm_group_label>
    <other_name>Mabthera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>cycle 1-6: 90mg/m² i.v., day 1-2, q28d</description>
    <arm_group_label>BR</arm_group_label>
    <other_name>Levact</other_name>
    <other_name>Ribomustin</other_name>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cycle 1-6: 250 mg/m² i.v., days 1-3, q28d</description>
    <arm_group_label>FCR</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>cycle 1-6: 25 mg/m² i.v., days 1-3, q28d</description>
    <arm_group_label>FCR</arm_group_label>
    <other_name>Fludura</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Confirmed diagnosis of B-cell chronic lymphocytic leukemia (CLL) meeting 1 of the
             following criteria:

          -  Binet stage C disease or stage B or A disease requiring treatment

          -  Binet stage B or A disease meeting ≥ 1 of the following:

          -  B-symptoms (e.g., night sweats, weight loss ≥ 10% within the past 6 months, fevers &gt;
             38°C or 100.4°F for ≥ 2 weeks without evidence of infection) or constitutional
             symptoms (e.g., fatigue)

               -  Progressive lymphocytosis, defined as peripheral lymphocyte count &gt; 5 x 10^9/L
                  (i.e., &gt; 50% increase over a 2-month period or doubling of peripheral blood
                  lymphocyte count &lt; 6 months)

               -  Evidence of progressive marrow failure as manifested by the development/worsening
                  of anemia and/or thrombocytopenia

               -  Massive, progressive, or painful splenomegaly or hypersplenism

               -  Massive lymph nodes or lymph node clusters (&gt; 10 cm in longest diameter) or
                  progressive or symptomatic lymphadenopathy

                    -  No 17p deletion by FISH

                    -  No aggressive B-cell cancer, such as Richter syndrome

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Life expectancy ≥ 6 months

          -  Total bilirubin ≤ 2 times upper limit of normal (ULN) (unless directly attributable to
             CLL)

          -  AST and ALT ≤ 2 times ULN (unless directly attributable to CLL)

          -  Creatinine clearance ≥ 70 mL/min (creatinine clearance is to be calculated only in
             patients with serum creatinine ≥ 1.1 mg/dL)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 6 months after
             completion of study therapy

          -  Hepatitis B and C negative

          -  HIV negative

          -  CIRS score &gt; 6 or a single score of 4 for one organ category

          -  No active secondary malignancy requiring treatment, except basal cell carcinoma or
             malignant tumor curatively treated by surgery, or successfully treated secondary
             malignancies in complete remission &gt; 5 years prior to enrollment

          -  No history of anaphylaxis following exposure to monoclonal antibodies

          -  No active bacterial, viral, or fungal infection

          -  No medical condition requiring prolonged use of oral corticosteroids (i.e., &gt; 1 month)

          -  No cerebral dysfunction or legal incapacity

          -  No circumstance that would preclude completion of the study or the required follow-up

        PRIOR CONCURRENT THERAPY:

          -  No prior CLL specific-chemotherapy, radiotherapy, and/or immunotherapy

               -  Prednisolone administered immediately prior to initiation of study therapy
                  allowed for very high lymphocyte counts

          -  No concurrent participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Eichhorst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Universitaetsklinik I at the University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik I at the University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dcllsg.de/en/trial/cll10/</url>
    <description>Click here for more information about this study: CLL10 (German CLL Study Group)</description>
  </link>
  <reference>
    <citation>Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J Clin Oncol. 2016 Nov 1;34(31):3758-3765. doi: 10.1200/JCO.2016.67.1305.</citation>
    <PMID>27573660</PMID>
  </reference>
  <reference>
    <citation>Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017 Oct;31(10):2251-2253. doi: 10.1038/leu.2017.221. Epub 2017 Jul 12.</citation>
    <PMID>28745332</PMID>
  </reference>
  <reference>
    <citation>Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18.</citation>
    <PMID>29255066</PMID>
  </reference>
  <results_reference>
    <citation>Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20.</citation>
    <PMID>27216274</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

